Evidence map›Paper›PMID 33152284›Full record

Trial reportThe Lancet. Oncology2020

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.

Ian Smith, John Robertson, Lucy Kilburn, Maggie Wilcox, Abigail Evans, Chris Holcombe, Kieran Horgan, Cliona Kirwan, Elizabeth Mallon, Mark Sibbering and 9 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02338310 (Trial of Perioperative Endocrine Therapy - Individualising Care), which is not on this map. Cited by 169 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 5 pooled it
31.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02338310 phase3active not recruitingnot on this map

Trial of Perioperative Endocrine Therapy - Individualising Care

TypeinterventionalSponsorInstitute of Cancer Research, United KingdomRan2008 to 2034Enrolled4,486ConditionsBreast CancerArmsAromatase Inhibitors
3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 5 syntheses or guidelines pooled it, 302 citations in OpenAlex.

  1. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ERClinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Ian SmithThe Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK. Electronic address: poetic-icrctsu@icr.ac.uk.
John RobertsonUniversity of Nottingham, Nottingham, UK; University Hospitals of Derby and Burton, Derby, UK.
Lucy KilburnThe Institute of Cancer Research, London, UK.
Maggie WilcoxIndependent Cancer Patients Voice, London, UK.
Abigail EvansPoole Hospital NHS Foundation Trust, Poole, UK.
Chris HolcombeLiverpool University Hospitals Foundation Trust, Liverpool, UK.
Kieran HorganBexley Cancer Centre, Leeds, UK.
Cliona KirwanUniversity of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Elizabeth MallonQueen Elizabeth University Hospital Glasgow, Govan, UK.
Mark SibberingUniversity Hospitals of Derby and Burton, Derby, UK.
Anthony SkeneRoyal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, UK.
Raghavan VidyaUniversity of Birmingham and Royal Wolverhampton NHS Trust, Wolverhampton, UK.
Maggie CheangThe Institute of Cancer Research, London, UK.
Jane BanerjiThe Institute of Cancer Research, London, UK.
James MordenThe Institute of Cancer Research, London, UK.
Kally SidhuThe Royal Marsden NHS Foundation Trust, London, UK.
Andrew DodsonThe Royal Marsden NHS Foundation Trust, London, UK.
Judith M BlissThe Institute of Cancer Research, London, UK.
Mitch DowsettThe Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
Institute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBPoole Hospital NHS Foundation Trust · GBQueen Elizabeth University Hospital · GBRoyal Bournemouth and Christchurch Hospitals NHS Foundation Trust · GBRoyal Derby Hospital · GBThe Patients Association · GBThe Royal Wolverhampton NHS Trust · GBUniversity Hospitals of Derby and Burton NHS Foundation Trust · GBUniversity of Liverpool · GB

Funding

Cancer Research UK 8671
6 · The paper itself

Abstract

backgroundPreoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 weeks (Ki67

methodsPOETIC was an open-label, multicentre, parallel-group, randomised, phase 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO performance status 0-1 and hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI (letrozole 2·5 mg per day orally or anastrozole 1 mg per day orally) for 14 days before and following surgery or no POAI (control). Adjuvant treatment was given as per UK standard local practice. Randomisation was done centrally by computer-generated permuted block method (variable block size of six or nine) and was stratified by hospital. Treatment allocation was not masked. The primary endpoint was time to recurrence. A key second objective explored association between Ki67 (dichotomised at 10%) and disease outcomes. The primary analysis for clinical endpoints was by modified intention to treat (excluding patients who withdrew consent). For Ki67 biomarker association and endpoint analysis, the evaluable population included all randomly assigned patients who had paired Ki67 values available. This study is registered with ClinicalTrials.gov, NCT02338310; the European Clinical Trials database, EudraCT2007-003877-21; and the ISRCTN registry, ISRCTN63882543. Recruitment is complete and long-term follow-up is ongoing.

findingsBetween Oct 13, 2008, and April 16, 2014, 4480 women were recruited and randomly assigned to POAI (n=2976) or control (n=1504). On Feb 6, 2018, median follow-up was 62·9 months (IQR 58·1-74·1). 434 (10%) of 4480 women had a breast cancer recurrence (280 [9%] POAI; 154 [10%] control), hazard ratio 0·92 (95% CI 0·75-1·12); p=0·40 with the proportion free from breast cancer recurrence at 5 years of 91·0% (95% CI 89·9-92·0) for patients in the POAI group and 90·4% (88·7-91·9) in the control group. Within the POAI-treated HER2-negative subpopulation, 5-year recurrence risk in women with low Ki67

interpretationPOAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67

fundingCancer Research UK.

Indexed as

AgedAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleHumansKi-67 AntigenMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentNeoplasm StagingPostmenopausePrognosisAromatase InhibitorsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaKi-67 AntigenMKI67 protein, human

Identifiers

PMID33152284
PMCPMC7606901
OpenAlexW3095872986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.